



REMARKS

Applicants submit this Amendment to insert the required references to SEQ ID NOS of the Sequence Listing filed concurrently herewith, to delete the Sequence Listing filed previously, and to indicate the insertion point for the Sequence Listing filed concurrently herewith. Applicants respectfully request examination on the merits of this application. Receipt of the initial Office Action on the merits is awaited.

Respectfully submitted,

July 20, 2001
Date

Stephen B. Maebius
Registration No. 35,264

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

In the specification:

Marked up version of specification starting at page 1, paragraph 4, lines 29-35:

Some synthetic peptides, deduced from these TSR units, have valuable biological properties. Thus, the CSVTCG (SEQ ID NO:21) units allow the adhesion of the plasmodium sporozoites to the hepatic cells, the CSVTCG (SEQ ID NO:21) and WXXW (SEQ ID NO:22) units allow cellular attachment in other biological models, BBXB (SEQ ID NO:23) (B being a basic amino acid) binds heparin and finally WSXWS (SEQ ID NO:24) binds certain growth factors.

In the claims:

Marked up version of claims:

1. (Amended) Peptide having at least the following amino acid sequence:

-W-S-A₁-C-S-A₂-C-G- (SEQ ID NO. 1)

in which A₁ and A₂ are amino acid sequences comprising 1 to 5 amino acids, with the exception of the peptides or polypeptides having one of the sequences:

-W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)

-W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)

-W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)

-W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)

-W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)

-W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)

-W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)

-T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)

-T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20).

9. (Amended) Use of a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

-W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)

-W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)

-W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)
-W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)
-W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)
-W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)
-W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)
-T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)
-T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20), for the
manufacture of a medicine intended for the regeneration of the nervous system cells.

10. (Amended) Use of a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

-W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)
-W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)
-W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)
-W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)
-W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)
-W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)
-W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)
-T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)
-T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20), for the
manufacture of a medicine intended for the treatment of neurodegenerative diseases.

11. (Amended) Use of a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

-W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)
-W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)
-W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)
-W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)
-W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)
-W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)
-W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)
-T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)

-T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20), for the manufacture of a medicine intended for the treatment of pathological conditions and traumas requiring regeneratoin of the nervous system cells and more particularly of their synaptic outgrowths.

12. (Amended) Use of a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

-W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)

-W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)

-W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)

-W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)

-W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)

-W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)

-W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)

-T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)

-T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20), for the manufacture of a medicine intended for the treatment of neuroblastomas.

13. (Amended) Additive for the cellular cultures of nerve cells, characterized in that it comprises a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

-W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)

-W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)

-W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)

-W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)

-W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)

-W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)

-W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)

-T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)

-T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20).

14. (Amended) Cellular expression vector, characterized in that it comprises a nucleic acid sequence expressing a peptide selected from the peptides according to one of Claims 1 to 7 and the peptides having the sequence:

-W-S-P-C-S-V-T-C-G- (SEQ ID NO. 2)

-W-S-S-C-S-V-T-C-G- (SEQ ID NO. 3)

-W-S-Q-C-S-V-T-C-G- (SEQ ID NO. 4)

-W-S-P-W-S-E-W-T-S-C-S-T-S-C-G-N-G-I-Q-Q-R-G-R (SEQ ID NO:15)

-W-S-H-W-S-P-W-S-S-C-S-V-T-C-G-D-G-V-I-T-R-I-R (SEQ ID NO:16)

-W-G-P-W-S-P-W-D-I-C-S-V-T-C-G-G-G-V-Q-K-R-S-R (SEQ ID NO:17)

-W-S-Q-C-S-V-Y-C-G (SEQ ID NO:18)

-T-E-W-S-A-C-S-K-S-C-G-M-G-F-S-T-R-V-T-N-R-N (SEQ ID NO:19)

-T-E-W-S-A-C-S-K-T-C-G-M-G-I-S-T-R-V-T-N-D-N (SEQ ID NO:20).